New Strategy For Treating Advanced Progressing Bile Duct Cancer | Latest News RSS feed

New Strategy For Treating Advanced Progressing Bile Duct Cancer - Latest News


New strategy for treating advanced, progressing bile duct cancer

... Cancer Society (MRSG-12-194-01-TBG), the Prostate Cancer Foundation, the National Institutes of Health (HG006508, CA202971, CA216432), the American Lung Association and Pelotonia. Ohio State ... read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

Study shows how treatment resistance develops in patients with bile duct cancer

A new study led by researchers at The Ohio ... targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. The study, reported in the journal Molecular ... read more

BridgeBio nabs accelerated review in U.S. for infigratinib for bile duct cancer

BridgeBio Pharma (NASDAQ:BBIO) is up 7% premarket on light volume in reaction to the FDA's Fast Track and Orphan Drug designations for infigratinib for the first-line treatment of advanced/metastatic ... read more

Looking for another news?


Basilea posts interim pivotal data on ArQule-partnered cancer drug

Derazantinib is designed to counter the pan-fibroblast growth factor receptor dysregulation that drives the bile duct cancer iCCA and the growth of ... which are associated with low response rates and ... read more


Revisiting RedHill Biopharma

H.L. Mencken Today, we revisit an interesting "Tier 3" stock in a company that made some significant progress in 2019 ... selective inhibitor with anti-inflammatory and anti-cancer activities, in an ... read more

Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

NEW YORK ... and bile duct) and pancreatic cancers. "AGEN1223 is a novel bispecific antibody designed to selectively deplete specific immune-suppressive cells called regulatory T cells. The ability to ... read more

The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling

January 06, 2020 07:30 ET | Source: BridgeBio Pharma, Inc. SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary QED Therapeutics announced today that it ... read more

BridgeBio Pharma's QED Therapeutics Receives...

SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast Track Designation in adults with ... read more

Day Three of the American Association for Cancer Research Medicine (AACR): Precision Medicine Emerges as a Theme

“We are proposing a new novel strategy to treat these patients for whom the standard of care is continued chemotherapy.” The study also confirms the importance of identifying specific gene mutations ... read more

Clinical Laboratory Tests Market Research Report Focusing on Leading Fortune Companies [2020-2027]

The global Clinical Laboratory Tests Market size accounted for $XX.XX million in 2019 with XX% CAGR, and it is expected to reach $XX.XX million by the end of 2027 with a CAGR of XX% from 2020 to 2027. read more

Study suggests new strategy for treating advanced, progressing bile duct cancer

A new study led by researchers at The Ohio ... targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. The study, reported in the journal Molecular ... read more

Study suggests new strategy for treating bile duct cancer

COLUMBUS — A new study led by researchers at The ... targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. The study, reported in the journal ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us